OR WAIT null SECS
CatSci has announced an expansion of its offering to include end-to-end services with an additional focus on lead optimization.
Contract research organization (CRO), CatSci, has announced an expansion of its offering to include end-to-end services with an additional focus on lead optimization, which will enable the company to play a role in drug discovery and development.
Traditionally, CatSci has focused on the latter stages of drug discovery and development; however, with its new lead optimization offering, the company’s clients will be able to nominate candidates faster. Through the new capability, CatSci will be able to broaden its customer base and as a result will also be able to offer more employment opportunities.
Dr Paul Bradley, head of Business Development, CatSci, said in a press release, “This is an important step for CatSci as we continue our rapid expansion. Delivering quality lead optimization projects for our customers will answer the demands of both the US and UK markets, increase our customer base and lead to long-term growth for the company.”